Drug Toxicity: Mechanisms, Assessment, and Safety Considerations
Abstract
Drug toxicity refers to the adverse effects of pharmaceutical compounds on biological systems, potentially leading to harmful outcomes. This review provides an in-depth analysis of the mechanisms, assessment methods, and types of drug toxicity, highlighting key factors influencing toxic responses and the importance of early detection and management.
Understanding drug toxicity is crucial for drug development, regulatory compliance, and ensuring patient safety.
How to cite this article:
Onwuka C, Usman Z. Drug Toxicity: Mechanisms,
Assessment, and Safety Considerations. J Durg
Dis Dev 2024; 8(1): 11-17.
References
Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein,
D. U., Wolfe, S. M., & Bor, D. H. (2002). Timing of new
black box warnings and withdrawals for prescription
medications. JAMA, 287(17), 2215-2220.
McDonnell, P. J., & Jacobs, M. R. (2002). Hospital
admissions resulting from preventable adverse drug
reactions. Annals of Pharmacotherapy, 36(9), 1331-
Uetrecht, J. (2007). Idiosyncratic drug reactions: Current
understanding. Annual Review of Pharmacology and
Toxicology, 47, 513-539.
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro,
A., Kolaja, G., & Lilly, P. (2000). Concordance of the
toxicity of pharmaceuticals in humans and in animals.
Regulatory Toxicology and Pharmacology, 32(1), 56-67.
Kola, I., & Landis, J. (2004). Can the pharmaceutical
industry reduce attrition rates? Nature Reviews Drug
Discovery, 3(8), 711-716.
Uetrecht JP. New concepts in immunology relevant to
idiosyncratic drug reactions: the “danger hypothesis”
and innate immune system. Chemical research in
toxicology. 1999 May 17;12(5):387-95.
Naisbitt DJ, Williams DP, Pirmohamed M, Kitteringham
NR, Park BK. Reactive metabolites and their role in
drug reactions. Current opinion in allergy and clinical
immunology. 2001 Aug 1;1(4):317-25.
Bailey J, Thew M, Balls M. Predicting human drug
toxicity and safety via animal tests: can any one species
predict drug toxicity in any other, and do monkeys
help?. Alternatives to Laboratory Animals. 2015
Dec;43(6):393-403.
MacDonald JS, Robertson RT. Toxicity testing in the
st century: a view from the pharmaceutical industry.
Toxicological Sciences. 2009 Jul 1;110(1):40-6.
Lin Z, Will Y. Evaluation of drugs with specific organ
toxicities in organ-specific cell lines. Toxicological
sciences. 2012 Mar 1;126(1):114-27.
Valentin JP, Hammond T. Safety and secondary
pharmacology: successes, threats, challenges and
opportunities. Journal of pharmacological and
toxicological methods. 2008 Sep 1;58(2):77-87.
Vargas HM, Amouzadeh HR, Engwall MJ. Nonclinical
strategy considerations for safety pharmacology:
evaluation of biopharmaceuticals. Expert opinion on
drug safety. 2013 Jan 1;12(1):91-102.
Nicolson TJ, Mellor HR, Roberts RR. Gender differences
in drug toxicity. Trends in pharmacological sciences.
Mar 1;31(3):108-14.
Basile AO, Yahi A, Tatonetti NP. Artificial intelligence
for drug toxicity and safety. Trends in pharmacological
sciences. 2019 Sep 1;40(9):624-35.
Syrowatka A, Song W, Amato MG, Foer D, Edrees H,
Kuznetsova M, Dulgarian S, Seger DL, Simona A, Bain
PA, Jackson GP. Key use cases for artificial intelligence
to reduce the frequency of adverse drug events: a
scoping review. The Lancet Digital Health. 2022 Feb
;4(2):e137-48.
Yang S, Kar S. Application of artificial intelligence and
machine learning in early detection of adverse drug
reactions (ADRs) and drug-induced toxicity. Artificial
Intelligence Chemistry. 2023 Aug 10:100011.
Liang L, Hu J, Sun G, Hong N, Wu G, He Y, Li Y, Hao T, Liu L,
Gong M. Artificial intelligence-based pharmacovigilance
in the setting of limited resources. Drug Safety. 2022
May;45(5):511-9.
Hauben M, Hartford CG. Artificial intelligence in
pharmacovigilance: scoping points to consider. Clinical
Therapeutics. 2021 Feb 1;43(2):372-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Drug Discovery and Development ( ISSN:2581-6861)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
